<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730024</url>
  </required_header>
  <id_info>
    <org_study_id>K0104-E</org_study_id>
    <nct_id>NCT04730024</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj</brief_title>
  <official_title>Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results From the K0104 Extension Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the&#xD;
      Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic&#xD;
      Dermatitis: 5-year Results from the K0104 Extension Study&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 27, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment (Rate of Adverse Event, Number of Participants with Adverse Event)</measure>
    <time_frame>for 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose EASI decreased by 50% or more at each evaluation visit compared to the baseline (EASI-50)</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 75% at each visit (EASI-75)</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change and Change in EASI from baseline</measure>
    <time_frame>for 5 years</time_frame>
    <description>EASI range is from 0 (clear) to 72 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Investigator's Global Assessment (IGA) score at each visit is 0 or 1</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose IGA at each visit is 0 or 1, or improved to 2 or higher</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose SCORing Atopic Dermatitis (SCORAD) INDEX was decreased from baseline by more than 50% at each visit (SCORAD-50)</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change and Change in SCORAD index from baseline at each visit</measure>
    <time_frame>for 5 years</time_frame>
    <description>SCORAD index range is from 0 (clear) to 103 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change in Body Surface Area (BSA)</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change in total serum Immunoglobulin E (IgE)</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change DLQI</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change POEM</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change Peak Pruritus NRS</measure>
    <time_frame>for 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Atopic Dermatitis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not applicable(observational study)</intervention_name>
    <description>Not applicable(observational study)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In this study (K0104-E), it was planned to select subjects who participated in the K0104&#xD;
        clinical trial, a parent study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject who enrolled K0104 Clinical Trial(parent study).&#xD;
&#xD;
          2. Subjects who understand and voluntarily sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are expected to be unable to perform at least one follow-up during this&#xD;
             study (K0104-E)&#xD;
&#xD;
          2. Subjects who has received/administered clinical trial drugs or medical devices by&#xD;
             participating in other clinical trials until the first visit of this trial (K0104-E)&#xD;
             after the completion of K0104 clinical trial&#xD;
&#xD;
          3. Subjects who are judged to be unsuitable for other researchers to participate in the&#xD;
             research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eundoek Yeo</last_name>
    <phone>82-2-888-1592</phone>
    <email>edyeo@kangstem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seulbi Lee</last_name>
    <phone>82-2-888-1592</phone>
    <email>sblee@kangstem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongguk University Medical Center</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

